TP53 and hepatocellular carcinoma: In addition, compared to the somatic mutation landscape from the TCGA HCC cohort, Chinese HCC patients exhibited a higher proportion of TERT mutations (32% [21/66] vs. 0.5% [2/365]), while the proportion of TP53 mutations was similar (30% [20/66] vs. 30% [110/365]) (Figure 2A, Figure S1C).